Core Insights - Small-cap stocks exhibit higher volatility and activity compared to large-cap stocks, making them more likely to become market leaders [1] Market Overview - As of November 5, there are 919 stocks with a circulating market value below 3 billion yuan, and 355 stocks with a circulating market value below 2 billion yuan [1] - A total of 1619 stocks have a total market value below 5 billion yuan, with 517 stocks below 3 billion yuan [1] Smallest Market Capitalization Stocks - The three stocks with the smallest circulating market values are: - *ST Yuan Cheng: 218 million yuan - *ST Gao Hong: 430 million yuan - Kuntai Co., Ltd.: 667 million yuan [1] - The three stocks with the smallest total market values are: - *ST Yuan Cheng: 218 million yuan - *ST Gao Hong: 440 million yuan - *ST Su Wu: 711 million yuan [1] Selected Stocks with Low Market Capitalization - A list of stocks with circulating market values below 2 billion yuan includes: - *ST Yuan Cheng: 2.18 billion yuan, PE ratio: N/A, Industry: Construction Decoration - *ST Gao Hong: 4.30 billion yuan, PE ratio: N/A, Industry: Communication - Kuntai Co., Ltd.: 6.67 billion yuan, PE ratio: 48.52, Industry: Automotive - Other notable stocks include: - Kangliyuan: 7.07 billion yuan, PE ratio: 36.58, Industry: Light Industry Manufacturing - *ST Su Wu: 7.11 billion yuan, PE ratio: N/A, Industry: Pharmaceutical Biology [1][2]

Core Insights - The average stock price in the A-share market is 13.85 yuan, with 24 stocks priced below 2 yuan, the lowest being *ST Gao Hong at 0.38 yuan [1] - Among the low-priced stocks, 9 are ST stocks, accounting for 37.50% of the total [1] - In terms of market performance, 17 of the low-priced stocks increased in value, with notable gains from HNA Holding, Yongtai Energy, and Guangtian Group, which rose by 3.31%, 2.47%, and 2.15% respectively [1] Low-Priced Stocks Summary - The lowest priced stock is *ST Gao Hong at 0.38 yuan, with a market-to-book ratio of 2.91 [1] - Other notable low-priced stocks include *ST Yuan Cheng at 0.67 yuan with a decline of 4.29%, and *ST Su Wu at 1.00 yuan with a decline of 1.96% [1] - The table lists various low-priced stocks along with their latest closing prices, daily price changes, turnover rates, and industry classifications [1][2]

Core Insights - The average stock price in the A-share market is 13.80 yuan, with 26 stocks priced below 2 yuan, the lowest being *ST Gao Hong at 0.38 yuan [1][2] - Among the low-priced stocks, 10 are ST stocks, accounting for 38.46% of the total [1] - The Shanghai Composite Index closed at 3960.19 points as of November 4 [1] Low-Priced Stocks Overview - The lowest priced stock is *ST Gao Hong at 0.38 yuan, followed by *ST Yuan Cheng at 0.70 yuan and *ST Su Wu at 1.02 yuan [1] - In terms of daily performance, *ST Hui Feng, *ST Su Wu, and Rongsheng Development saw increases of 4.85%, 3.03%, and 1.22% respectively, while *ST Yuan Cheng, ST Lingnan, and Chongqing Steel experienced declines of 5.41%, 3.02%, and 1.30% respectively [1] Detailed Low-Priced Stocks Table - The table lists various low-priced stocks along with their latest closing prices, daily change percentages, turnover rates, price-to-book ratios, and industries [1][2] - Notable stocks include *ST Hui Feng with a daily increase of 4.85% and *ST Yuan Cheng with a decline of 5.41% [1]

Core Viewpoint - *ST Suwu is facing significant challenges, including a sharp decline in revenue and net profit, alongside ongoing arbitration regarding the exclusive agency rights for the AestheFill product, which is critical to its business operations [2][5][6]. Financial Performance - In Q3 2025, *ST Suwu reported a revenue decline of 63.93% year-on-year, amounting to 148 million yuan, with a net profit attributable to shareholders of approximately -43 million yuan, a drastic decrease of 308.72% compared to the previous year [2][4]. - For the first three quarters of the year, the company's revenue fell by 38.85% to 784 million yuan, and the net profit decreased by 294.03% to -87.47 million yuan, primarily due to significant impairment provisions for trade receivables [5][6]. Business Segments - The pharmaceutical business generated a total revenue of 468 million yuan, down 55.79% year-on-year, while the aesthetic biomedical segment achieved a revenue of 304 million yuan, reflecting a growth of 52.78% [5][6]. - The AestheFill product, crucial for the aesthetic segment, faced sales disruptions due to an ongoing arbitration case, which has created uncertainty for the company's future performance in this area [6][7]. Regulatory and Legal Issues - *ST Suwu is under scrutiny from the China Securities Regulatory Commission (CSRC) for alleged violations of information disclosure, leading to a formal investigation and potential penalties [7][9]. - The company has been implicated in inflating revenue figures by approximately 1.771 billion yuan from 2020 to 2023, raising concerns about its financial integrity and leading to multiple delisting risks [8][9]. Management Changes - Recent changes in the company's management include the resignation of the securities affairs representative, with a new appointment made to assist the board in fulfilling its responsibilities [9].

New Stock Issuance - Multiple new stock issuances are scheduled for November 4, 2025, across various companies, including ST Zhongdi (000609) and Pingtan Development (000592) which reported significant abnormal fluctuations[1] - Jiangbolong (301308) and Xiangnong Xinchuan (300475) are among the companies with recent announcements prior to November 4, 2025[1] Abnormal Fluctuations - Pingtan Development (000592) reported severe abnormal fluctuations on November 4, 2025, indicating potential volatility in its stock performance[1] - Other companies such as ST Panda (600599) and ST Huapeng (603021) also reported abnormal fluctuations on the same date, suggesting a trend of instability in the market[1] Market Trends - The report highlights a growing trend of companies experiencing abnormal stock price movements, which may indicate increased market volatility and investor caution[1] - The presence of multiple companies with abnormal fluctuations could signal a broader market trend that investors should monitor closely[1]

Core Points - The average stock price of A-shares is 13.91 yuan, with 27 stocks priced below 2 yuan, the lowest being *ST Gao Hong at 0.38 yuan [1][2] - As of November 3, the Shanghai Composite Index closed at 3976.52 points, indicating a relatively low proportion of both high-priced and low-priced stocks in the A-share market [1] - Among the low-priced stocks, 10 are ST stocks, accounting for 37.04% of the total [1] Market Performance - Out of the low-priced stocks, 21 saw an increase today, with notable gains from Yabo Co., HNA Holding, and *ST Yun Wang, which rose by 3.39%, 3.39%, and 3.21% respectively [1] - Conversely, 4 stocks experienced declines, with *ST Yuan Cheng, ST Lingnan, and *ST Jin Ke dropping by 5.13%, 2.93%, and 1.43% respectively [1] Low-Priced Stock Rankings - The table lists various low-priced stocks, including their latest closing prices, daily price changes, turnover rates, price-to-book ratios, and industries [1][2] - Notable low-priced stocks include *ST Gao Hong (0.38 yuan), *ST Yuan Cheng (0.74 yuan), and *ST Su Wu (0.99 yuan) [1] - The highest daily gainers among low-priced stocks are Yabo Co. and HNA Holding, both increasing by 3.39% [1]

Core Viewpoint - *ST Suwu is facing significant financial challenges, including a substantial decline in revenue and net profit, alongside risks of delisting due to stock price falling below 1 yuan and regulatory scrutiny for financial misconduct [1][2][4]. Stock Performance - As of October 31, 2025, *ST Suwu's stock closed at 0.99 yuan, down 6.6% from the previous week [1]. - The stock reached a high of 1.04 yuan and a low of 0.91 yuan during the week [1]. - The current market capitalization is 704 million yuan, ranking 151 out of 151 in the chemical pharmaceutical sector and 5161 out of 5163 in the A-share market [1]. Shareholder Changes - As of September 30, 2025, the number of shareholders decreased to 67,400, a reduction of 1.99% from June 30, 2025 [1][3]. - The average number of shares held per shareholder increased from 10,400 to 10,500, with an average holding value of 10,000 yuan [1]. Financial Performance - For the first three quarters of 2025, *ST Suwu reported a main revenue of 784 million yuan, a year-on-year decrease of 38.85% [1]. - The net profit attributable to shareholders was -87.468 million yuan, down 294.03% year-on-year [1]. - The third quarter alone saw a revenue of 148 million yuan, a decline of 63.93%, with a net profit of -43.0502 million yuan, down 308.72% year-on-year [1]. Regulatory and Legal Issues - The company received a notice from the China Securities Regulatory Commission regarding potential penalties for false financial reporting from 2020 to 2023, which may lead to mandatory delisting [2][4]. - The stock price fell below 1 yuan, which could trigger a delisting process if it remains below this threshold for 20 consecutive trading days [2][4]. - The company is also facing multiple risks, including financial and regulatory issues, with a significant amount of related party non-operating fund occupation reported [2][4]. Business Segment Performance - For the first nine months of 2025, the medical beauty and biotechnology segment generated 304 million yuan in revenue, a year-on-year increase of 52.78% [3]. - The pharmaceutical segment reported a revenue of 468 million yuan, a decline of 55.79% year-on-year [3].

Core Viewpoint - Jiangsu Wuzhong (ST Suwu) is facing imminent delisting risks due to significant financial misconduct and operational decline, with a potential forced delisting warning issued by the China Securities Regulatory Commission (CSRC) [2][5] Financial Performance - For the first three quarters, Jiangsu Wuzhong reported a net loss of 87.468 million yuan, with revenue decreasing by nearly 40% year-on-year, leading to a cumulative loss of 500 million yuan in undistributed profits [2][6] - The company's revenue for the first three quarters was 784 million yuan, a year-on-year decrease of 38.85%, with a net profit loss of 94.7225 million yuan after excluding non-recurring items [6][7] Legal and Regulatory Issues - The CSRC has identified Jiangsu Wuzhong's major violations, including failure to disclose the actual controller, inflating revenue and profits, and not reporting non-operating fund occupation by related parties [3][5] - The company has been under investigation since February, and its stock price has dropped 88% since then, with the latest closing price at 0.99 yuan [5][6] Operational Challenges - Jiangsu Wuzhong's core pharmaceutical business has seen a 55.79% decline in revenue, while its medical beauty segment, once seen as a growth driver, is now at risk due to the termination of exclusive distribution rights for its key product, AestheFill [7][8] - The company is experiencing severe cash flow issues, with operational capabilities severely hampered by the occupation of funds by related parties, which increased from 127 million yuan at the end of 2020 to 1.693 billion yuan by the end of 2023 [4][6] Shareholder Impact - As of September 30, Jiangsu Wuzhong had 67,400 shareholders, facing imminent delisting risks if the CSRC confirms the violations or if the stock price remains below 1 yuan for 20 consecutive trading days [8]

Core Viewpoint - Jiangsu Wuzhong (*ST Suwu*) is facing imminent delisting risks due to significant financial losses, operational stagnation, and regulatory violations, with a net profit loss of 87.468 million yuan and a nearly 40% year-on-year revenue decline in the third quarter [3][4]. Group 1: Delisting Risks - The primary risk for Jiangsu Wuzhong is the potential for mandatory delisting due to major violations, as identified by the China Securities Regulatory Commission (CSRC) [5]. - The company has been found guilty of three major violations, including failing to disclose the actual controller, inflating revenue and profits, and not reporting non-operational fund usage by related parties [5][6]. - The stock price has plummeted 88% since the CSRC investigation began, with the latest closing price at 0.99 yuan, hovering near the delisting threshold of 1 yuan [7]. Group 2: Financial Performance - Jiangsu Wuzhong reported a 38.85% decrease in revenue for the first three quarters, totaling 784 million yuan, with a net profit loss of 87.468 million yuan [9]. - The third quarter alone saw a staggering 63.93% year-on-year revenue drop, with a net profit loss of 43.0502 million yuan, marking a significant operational decline [9][10]. - The company's cumulative undistributed losses reached 505 million yuan by the end of the third quarter, the highest since its listing [9]. Group 3: Business Operations - The core pharmaceutical business has seen a 55.79% decline in revenue, while the medical beauty segment, previously seen as a growth driver, is now at risk due to the termination of exclusive distribution rights for a key product [10][11]. - The medical beauty segment's revenue was 303 million yuan, a 52.78% increase, but the loss of exclusive rights for the AestheFill product could severely impact future earnings [10][11]. - The company is facing severe cash flow issues, with operational funds critically low due to significant related party fund usage, which increased from 127 million yuan in 2020 to 1.693 billion yuan in 2023, consuming nearly all net assets [6][9].

Core Viewpoint - Jiangsu Wuzhong (600200.SH) is facing imminent delisting risks due to multiple violations, including significant financial losses and operational stagnation, as highlighted in recent announcements and financial reports [1][2][4]. Group 1: Delisting Risks - Jiangsu Wuzhong has issued a risk warning regarding potential delisting due to a face value breach, with a stock price currently at 0.99 yuan, down 89% year-to-date [1][2]. - The company is under investigation by the China Securities Regulatory Commission (CSRC) for major violations, including failure to disclose the actual controller and inflating financial figures from 2018 to 2023 [2][3]. - The company has been identified as having significant non-operational fund occupation by related parties, with amounts soaring from 127 million yuan in 2020 to 1.693 billion yuan in 2023, representing 96.09% of net assets [3]. Group 2: Financial Performance - Jiangsu Wuzhong reported a net loss of 87.468 million yuan for the first three quarters, with revenue dropping by 38.85% to 784 million yuan [1][4]. - The company's pharmaceutical business saw a 55.79% decline in revenue, while the medical beauty segment, previously seen as a growth area, is now under threat due to the termination of exclusive distribution rights for a key product [5][6]. - The third quarter alone showed a staggering revenue drop of 63.93% compared to the previous quarter, with a net loss of 43.0502 million yuan, marking a significant operational downturn [5][6].